| Verheye, Stefan |
NCT05033964: The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions |
|
|
| Active, not recruiting | 2 | 200 | Europe, RoW | Percutaneous Coronary Intervention with drug eluting stents | Elixir Medical Corporation | Coronary Artery Disease | 12/22 | 03/26 | | |
CAPTURE, NCT03571789: Carotid Artery Implant for Trapping Upstream Emboli for Preventing Stroke in Atrial Fibrillation Patients |
|
|
| Active, not recruiting | N/A | 25 | Europe, RoW | Vine™ | Javelin Medical | Atrial Fibrillation | 12/18 | 11/28 | | |
BIOSOLVE-IV, NCT02817802: BIOTRONIKS - Safety and Performance in de NOvo Lesion of NatiVE Coronary Arteries With Magmaris- Registry: |
|
|
| Active, not recruiting | N/A | 2066 | Europe, RoW | Magmaris | Biotronik AG | Coronary Artery Disease | 07/20 | 10/25 | | |
NCT04289870: Innoventric Trillium™ Stent Graft First-in-Human (FIH) Study |
|
|
| Active, not recruiting | N/A | 20 | Europe, RoW | Trillium™ | Innoventric LTD | Tricuspid Regurgitation | 07/23 | 06/26 | | |
| Recruiting | N/A | 20 | Europe | Topaz TTVR System | TRiCares | Tricuspid Regurgitation | 12/24 | 05/29 | | |
PINNACLE I, NCT05828173: A Clinical Trial to Assess the Elixir Medical LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter |
|
|
| Active, not recruiting | N/A | 60 | Europe | LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter (LithiX Coronary HCIVLC; LithiX) | Elixir Medical Corporation | Coronary Artery Disease | 04/24 | 09/24 | | |
CAPTURE2, NCT03892824: Carotid Artery Implant for Preventing Stroke in Atrial Fibrillation Patients Taking Oral Anticoagulants |
|
|
| Active, not recruiting | N/A | 100 | Europe, RoW | Vine™ Embolic Protection System | Javelin Medical, Genae | Atrial Fibrillation, Stroke | 11/22 | 10/24 | | |
NCT02710435: REDUCER-I: An Observational Study of the Neovasc Reducer™ System |
|
|
| Active, not recruiting | N/A | 400 | Europe | Reducer System, Reducer | Neovasc Inc., Shockwave Medical, Inc. | Angina Pectoris, Angina Pectoris, Stable, Chronic Stable Angina | 11/23 | 12/28 | | |
| Active, not recruiting | N/A | 800 | Europe, Canada, US, RoW | Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum) | Medtronic Cardiovascular | Symptomatic Aortic Stenosis | 12/23 | 12/24 | | |
| Recruiting | N/A | 500 | Europe, RoW | Robotic-assisted PCI | Robocath, European Cardiovascular Research Center | Coronary Disease | 05/26 | 06/26 | | |
| Zachee, Pierre |
NCT03083574: Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD) |
|
|
| Recruiting | 2 | 100 | Europe | Photopheresis Theraflex ECP™ | Jules Bordet Institute, Macopharma, Belgian Hematological Society | Refractory Chronic Graft Versus Host Disease (cGVHD) | 09/22 | 09/23 | | |
| VENDITTI, Adriano |
| Recruiting | 3 | 172 | Europe | Cytarabine, Daunorubicin, Midostaurin, Cytarabine HD | Gruppo Italiano Malattie EMatologiche dell'Adulto, MYNERVA (MYeloid Neoplasms Research Venture AIRC) programma speciale finanziato dall'AIRC - Associazione Italiana per la, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus | Acute Myeloid Leukemia With FLT3/ITD Mutation | 12/22 | 08/25 | | |
| Recruiting | 3 | 414 | Europe | Gemtuzumab Ozogamicin | Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L. | Acute Myeloid Leukemia | 04/25 | 04/27 | | |
| Recruiting | 3 | 322 | Europe, Canada, US | Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF | Arog Pharmaceuticals, Inc. | Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations | 10/24 | 10/24 | | |
| Not yet recruiting | 3 | 339 | Europe, RoW | High intensity therapies, Low intensity therapies | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European Leukemia Net, Fundacion Para La Investigacion Hospital La Fe, Ostdeutsche Studiengruppe Haematologie Und Onkologie e.V., Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, TIMELEX | Acute Myeloid Leukemia, Relapse/Recurrence | 01/28 | 01/28 | | |
RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined with Venetoclax for Treatment of Relapsed/Refractory AML |
|
|
| Recruiting | 2 | 98 | Europe | RVU120, SEL120, Venetoclax | Ryvu Therapeutics SA | Acute Myeloid Leukemia | 02/26 | 09/26 | | |
| Recruiting | 2 | 94 | Europe, Canada | RVU120, SEL120 | Ryvu Therapeutics SA | Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome | 02/26 | 09/26 | | |
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance |
|
|
| Recruiting | N/A | 250 | Europe | | Ospedale di Circolo - Fondazione Macchi | SARS-CoV-2 Infection, Hematological Malignancies | 10/22 | 10/22 | | |
GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96 |
|
|
| Recruiting | N/A | 104 | Europe | Venetoclax plus HMA | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia | 12/22 | 12/23 | | |
| Recruiting | N/A | 4000 | Europe | Registration into the STREAM platform | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European LeukemiaNet, Fundacion Para La Investigacion Hospital La Fe, Ostedusche Hematology and Oncology Study Group, Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, Time.Lex | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | 07/32 | 07/32 | | |
| Bourgeois, Stefan |
NCT05276297 / 2021-003567-10: A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy |
|
|
| Active, not recruiting | 2 | 184 | Europe, RoW | GSK3228836, Bepirovirsen, GSK3528869A, Control | GlaxoSmithKline, GlaxoSmithKline Biologicals | Hepatitis B, Chronic | 02/26 | 02/26 | | |
NCT03866187 / 2017-001452-55: Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection |
|
|
| Terminated | 1/2 | 135 | Europe, RoW | ChAd155-hIi-HBV low dose formulation, ChAd155-hIi-HBV high dose formulation, HBc-HBs/AS01B-4 low dose formulation, HBc-HBs/AS01B-4 high dose formulation, MVA-HBV low dose formulation, MVA-HBV high dose formulation, Placebo | GlaxoSmithKline, GlaxoSmithKline Biologicals | Hepatitis B, Chronic | 10/24 | 10/24 | | |
| Recruiting | N/A | 100 | Europe | Blood sampling, questionaires | Hasselt University, Ziekenhuis Oost-Limburg, Jessa Hospital, Algemeen Ziekenhuis Vesalius, CAD Limburg, Sint-Trudo, Free Clinic Antwerp, Ziekenhuis Netwerk Antwerpen (ZNA), Clinique Saint Joseph, Liège, Centre Hospitalier Universitaire Saint Pierre, Algemeen Ziekenhuis Maria Middelares | Hepatitis C Virus Infection, Response to Therapy of, Drug Use | 02/22 | 02/22 | | |
| Active, not recruiting | N/A | 156 | Europe | Cessation of ongoing treatment | University Hospital, Antwerp, Universiteit Antwerpen | Chronic Hepatitis B | 12/25 | 12/25 | | |
| ANGUILLE, Sébastien |
| Active, not recruiting | 2 | 130 | Europe | DC vaccine | Zwi Berneman, Kom Op Tegen Kanker, Stichting tegen Kanker, Research Foundation Flanders | Acute Myeloid Leukemia | 12/25 | 12/27 | | |
| Active, not recruiting | 1/2 | 28 | Europe | dendritic cell vaccination plus chemotherapy, chemoimmunotherapy | University Hospital, Antwerp, Kom Op Tegen Kanker, Stichting tegen Kanker | Malignant Pleural Mesothelioma | 03/25 | 03/25 | | |
IMMUNICY-1, NCT04613557: Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 1 | 18 | Europe, US | CYAD-211, Endoxan, cyclophosphamide, Fludara, Fludarabine | Celyad Oncology SA | Relapse/Refractory Multiple Myeloma | 12/22 | 02/37 | | |
ApoAML, NCT05506332: Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 10 | Europe | Venetoclax, 6-mercaptopurine | University Hospital, Antwerp | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | 12/24 | 12/26 | | |
| Breems, Dimitri A |
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy |
|
|
| Active, not recruiting | 3 | 777 | Europe, RoW | Gilteritinib, ASP2215, Midostaurin, Rydapt | Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | 10/25 | 06/33 | | |
Predictor2, NCT03887156: Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft |
|
|
| Recruiting | 2/3 | 227 | Europe | Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test | Assistance Publique - Hôpitaux de Paris, SATT, SNC Graft Versus Host Disease, Imagine Institute, Axonal-Biostatem, CERBA laboratory | Acute Myeloid Leukemia in Remission, Lymphoma in Remission, Non-progressive Myeloproliferative Syndrome, Myelodysplasia With Stable Blasts is Cell Number and < 10% of Blastocysts, Acute Leukemia Biphenotypic in Remission, Acute Lymphoblastic Leukemia | 03/23 | 03/23 | | |
NCT03852407: Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning |
|
|
| Recruiting | 2 | 114 | Europe | Thymoglobulin, ATG, Melphalan, alkeran, Fludarabine, Cyclophosphamid, PTCy | University of Liege, Belgian Hematological Society | Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia in Remission, Myeloproliferative Syndrome, Myeloproliferative Disorder, Acute Lymphoid Leukemia in Remission, Multiple Myeloma, Chronic Lymphoid Leukemia, Non Hodgkin Lymphoma, Hodgkin Lymphoma | 11/33 | 11/38 | | |
BYON4413.001, NCT06359002: Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms. |
|
|
| Recruiting | 1 | 100 | Europe | BYON4413 | Byondis B.V. | Relapsed / Refractory AML, Relapsed / Refractory MDS | 12/26 | 03/27 | | |
| Wu, Kalung |
| Active, not recruiting | 3 | 240 | Europe, Canada, US, RoW | Brentuximab vedotin, Rituximab, Lenalidomide, Placebo | Seagen Inc. | Diffuse Large B-cell Lymphoma | 05/25 | 04/27 | | |
|
| Batjoens, Hedwig |
CAPTURE2, NCT03892824: Carotid Artery Implant for Preventing Stroke in Atrial Fibrillation Patients Taking Oral Anticoagulants |
|
|
| Active, not recruiting | N/A | 100 | Europe, RoW | Vine™ Embolic Protection System | Javelin Medical, Genae | Atrial Fibrillation, Stroke | 11/22 | 10/24 | | |
NCT05477602: The Automated Calculation of AF Cycle Length and Complexity Using a Novel EP Recording System |
|
|
| Recruiting | N/A | 30 | Europe | Cardiac Ablation for the treatment of persistent Atrial Fibrillation, Persistent AF Ablation | CathVision ApS, AKRN Consulting | Atrial Fibrillation | 12/24 | 12/25 | | |
GPfIRE, NCT06647485: Evaluation of the Impact of Pulsed Field Ablation on Autonomic Nervous System Modulation in Paroxysmal Atrial Fibrillation |
|
|
| Not yet recruiting | N/A | 105 | Europe | PF-only PVI, Hybrid PVI, RF-only PVI | VZW Cardiovascular Research Center Aalst, Biosense Webster, Inc. | Atrial Fibrillation (AF), Paroxysmal AF | 07/25 | 07/26 | | |
| Breems, Local Investigator: Dimitri |
| Active, not recruiting | 2 | 130 | Europe | DC vaccine | Zwi Berneman, Kom Op Tegen Kanker, Stichting tegen Kanker, Research Foundation Flanders | Acute Myeloid Leukemia | 12/25 | 12/27 | | |
| Joris, Inge |
NCT04289870: Innoventric Trillium™ Stent Graft First-in-Human (FIH) Study |
|
|
| Active, not recruiting | N/A | 20 | Europe, RoW | Trillium™ | Innoventric LTD | Tricuspid Regurgitation | 07/23 | 06/26 | | |
| Lung, Wu Ka |
| No trials found |
